Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | October 30, 2025 | November 03, 2025 |
| INTERPACE BIOSCIENCES, INC.IDXG · Entity 7296 | Director | August 20, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date October 30, 2025 · Filed November 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,411 |
Reported balance
After 2025-10-30 transaction · row 1
1 source rowRow 1 · 2025-10-30 · Grant · Acquired 1,640 · Balance 15,411 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30 | Direct | 3,777 |
Reported balance
After 2025-10-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-10-30 · Grant · Acquired 3,777 · Balance 3,777 F1: This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2027-10-26 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 12,500 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.96 · Expires 2028-10-25 | Direct | 7,592 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 7,592 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24 | Direct | 8,044 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 8,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29 | Direct | 6,028 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 6,028 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28 | Direct | 2,532 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 2,532 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27 | Direct | 3,460 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 3,460 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26 | Direct | 3,937 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 3,937 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24 | Direct | 3,511 |
Reported balance
Holding disclosure · report date 2025-10-30 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 3,511 |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
INTERPACE BIOSCIENCES, INC.
Report date August 20, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 69,252 |
Reported balance
After 2026-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-20 · Grant · Acquired 69,252 · Balance 69,252 F1: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc. F2: The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.
F2: The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RESPONSE BIOMEDICAL CORP
Report date November 29, 2016 · Filed December 01, 2016
Section 16 reporting ended · disclosed 2016-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 1
1 source rowRow 1 · 2016-11-29 · Disposition to issuer · Disposed 73,850 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Arrangement by and between the issuer and 1077801 B.C. Ltd., dated June 16, 2016 (the "Arrangement"), pursuant to which 1077801 B.C. Ltd. acquired all of the outstanding common shares of the issuer (other than those rolled over into the purchaser) in exchange for cash consideration of $1.12 CDN per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2022-04-02 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-11-29 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Prices shown are denominated in Canadian dollars. F4: Pursuant to the terms of the Arrangement, out of money stock options were cancelled. F3: 100% of the options vest fully on the date which is one year after the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2023-03-14 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-29 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Prices shown are denominated in Canadian dollars. F4: Pursuant to the terms of the Arrangement, out of money stock options were cancelled. F3: 100% of the options vest fully on the date which is one year after the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2024-03-19 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-11-29 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Prices shown are denominated in Canadian dollars. F4: Pursuant to the terms of the Arrangement, out of money stock options were cancelled. F3: 100% of the options vest fully on the date which is one year after the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.92 · Expires 2025-03-19 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-11-29 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Prices shown are denominated in Canadian dollars. F6: In connection with the Arrangement, all outstanding options to purchase common shares of the issuer as of immediately prior to the effective time of the Arrangement, were deemed unconditionally vested and exercisable, and subsequently cancelled in exchange for cash payment equal to the difference between the per share consideration of $1.12 CDN and the per share exercise price of such option multiplied by the number of common shares issuable pursuant to such option, less applicable withholdings. F5: 100% of the options vest on March 20, 2016, subject to the reporting person's continued service as a director of the Company through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2026-03-23 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-11-29 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Prices shown are denominated in Canadian dollars. F6: In connection with the Arrangement, all outstanding options to purchase common shares of the issuer as of immediately prior to the effective time of the Arrangement, were deemed unconditionally vested and exercisable, and subsequently cancelled in exchange for cash payment equal to the difference between the per share consideration of $1.12 CDN and the per share exercise price of such option multiplied by the number of common shares issuable pursuant to such option, less applicable withholdings. F7: Subject to the reporting person's continued service as a director of the company through each vesting date, 100% of the shares subject to the option shall vest and become exercisable on March 24, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Arrangement by and between the issuer and 1077801 B.C. Ltd., dated June 16, 2016 (the "Arrangement"), pursuant to which 1077801 B.C. Ltd. acquired all of the outstanding common shares of the issuer (other than those rolled over into the purchaser) in exchange for cash consideration of $1.12 CDN per share.
F2: Prices shown are denominated in Canadian dollars.
F3: 100% of the options vest fully on the date which is one year after the date of grant.
F4: Pursuant to the terms of the Arrangement, out of money stock options were cancelled.
F5: 100% of the options vest on March 20, 2016, subject to the reporting person's continued service as a director of the Company through each vesting date.
F6: In connection with the Arrangement, all outstanding options to purchase common shares of the issuer as of immediately prior to the effective time of the Arrangement, were deemed unconditionally vested and exercisable, and subsequently cancelled in exchange for cash payment equal to the difference between the per share consideration of $1.12 CDN and the per share exercise price of such option multiplied by the number of common shares issuable pursuant to such option, less applicable withholdings.
F7: Subject to the reporting person's continued service as a director of the company through each vesting date, 100% of the shares subject to the option shall vest and become exercisable on March 24, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 20, 2026 21:02 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantRestricted Stock Units · Derivative | 69,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-039504 · ownership.xml · derivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,252 Underlying: Common Stock · 69,252 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:37 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000024 · form4.xml · derivative · entry 10 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:37 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000024 · form4.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,411 Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:44 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018034 · form4.xml · derivative · entry 9 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:44 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018034 · form4.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,771 Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019848 · form4.xml · derivative · entry 8 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019848 · form4.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,309 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010914 · form4-10312022_021040.xml · derivative · entry 2 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010914 · form4-10312022_021040.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,671 Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:37 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000397 · edgar.xml · derivative · entry 6 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:37 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000397 · edgar.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,333 Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006491 · primarydocument.xml · derivative · entry 2 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006491 · primarydocument.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,139 Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 23:58 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantStock Option (right to buy) · Derivative | 29,000 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001493152-20-013113 · ownership.xml · derivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2030-07-08 F1 · derivative.exercise_date: The stock option is eligible to vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000016 · edgar.xml · derivative · entry 4 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000016 · edgar.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,748 Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004305 · primarydocument.xml · derivative · entry 2 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004305 · primarydocument.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,253 Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:31 UTC | INTERPACE BIOSCIENCES, INC. IDGX · Entity 7296 | GrantStock Option (right to buy) · Derivative | 19,200 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001493152-18-003191 · form4.xml · derivative · entry 2 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Underlying: Common Stock · 19,200 shares Expires 2018-03-07 F4 · derivative.exercise_date: The option award vests and becomes exercisable over a three-year period, in equal installments, commencing on March 7, 2019, subject to the reporting person's continued service with the Issuer. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:31 UTC | INTERPACE BIOSCIENCES, INC. IDGX · Entity 7296 | GrantCommon Stock | 4,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-003191 · form4.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,569 F1 · shares: The restricted units vest annually, in equal installments, over a three-year period, commencing on March 7, 2019. F2 · price: Each restricted unit represents the contingent right to receive one share of common stock of Interpace Diagnostics Group, Inc. (the "Issuer"). F3 · balance_after: Reflects 1-for-10 reverse stock split, effective as of December 28, 2016. Read SEC document |
| October 26, 2017 Filed Oct 31, 2017 15:37 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003392 · primarydocument.xml · derivative · entry 2 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2017) or the date of Bio-Techne 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 31, 2017 15:37 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003392 · primarydocument.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739 Read SEC document |
| September 25, 2017 Filed Sep 26, 2017 21:26 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001493152-17-010935 · form4.xml · derivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2018-09-25 F1 · derivative.exercise_date: The stock option award vests and becomes exercisable over a one-year period, in twelve equal installments, subject to the reporting person's continued service with the issuer. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:06 UTC | INTERPACE BIOSCIENCES, INC. IDGX · Entity 7296 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001192482-17-000073 · edgar.xml · derivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-03-15 F1 · derivative.exercise_date: The option award vests and becomes exercisable over a one-year period, commencing on March 15, 2017, in twelve equal installments, on the 14th day of each calendar month, subject to the reporting person's continued service with the issuer. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 21:11 UTC | RESPONSE BIOMEDICAL CORP RBM · Entity 180768 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $0.85 | Not disclosed |
DisclosureSEC source: 0001437749-16-042842 · rdgdoc.xml · derivative · entry 6 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-03-23 F2 · derivative.exercise_price: Prices shown are denominated in Canadian dollars. F6 · price: In connection with the Arrangement, all outstanding options to purchase common shares of the issuer as of immediately prior to the effective time of the Arrangement, were deemed unconditionally vested and exercisable, and subsequently cancelled in exchange for cash payment equal to the difference between the per share consideration of $1.12 CDN and the per share exercise price of such option multiplied by the number of common shares issuable pursuant to such option, less applicable withholdings. F7 · derivative.exercise_date: Subject to the reporting person's continued service as a director of the company through each vesting date, 100% of the shares subject to the option shall vest and become exercisable on March 24, 2017. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 21:11 UTC | RESPONSE BIOMEDICAL CORP RBM · Entity 180768 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $0.92 | Not disclosed |
DisclosureSEC source: 0001437749-16-042842 · rdgdoc.xml · derivative · entry 5 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-03-19 F2 · derivative.exercise_price: Prices shown are denominated in Canadian dollars. F6 · price: In connection with the Arrangement, all outstanding options to purchase common shares of the issuer as of immediately prior to the effective time of the Arrangement, were deemed unconditionally vested and exercisable, and subsequently cancelled in exchange for cash payment equal to the difference between the per share consideration of $1.12 CDN and the per share exercise price of such option multiplied by the number of common shares issuable pursuant to such option, less applicable withholdings. F5 · derivative.exercise_date: 100% of the options vest on March 20, 2016, subject to the reporting person's continued service as a director of the Company through each vesting date. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 21:11 UTC | RESPONSE BIOMEDICAL CORP RBM · Entity 180768 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001437749-16-042842 · rdgdoc.xml · derivative · entry 4 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-03-19 F2 · derivative.exercise_price: Prices shown are denominated in Canadian dollars. F4 · price: Pursuant to the terms of the Arrangement, out of money stock options were cancelled. F3 · derivative.exercise_date: 100% of the options vest fully on the date which is one year after the date of grant. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 21:11 UTC | RESPONSE BIOMEDICAL CORP RBM · Entity 180768 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $3.10 | Not disclosed |
DisclosureSEC source: 0001437749-16-042842 · rdgdoc.xml · derivative · entry 3 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-03-14 F2 · derivative.exercise_price: Prices shown are denominated in Canadian dollars. F4 · price: Pursuant to the terms of the Arrangement, out of money stock options were cancelled. F3 · derivative.exercise_date: 100% of the options vest fully on the date which is one year after the date of grant. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 21:11 UTC | RESPONSE BIOMEDICAL CORP RBM · Entity 180768 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $2.20 | Not disclosed |
DisclosureSEC source: 0001437749-16-042842 · rdgdoc.xml · derivative · entry 2 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-04-02 F2 · derivative.exercise_price: Prices shown are denominated in Canadian dollars. F4 · price: Pursuant to the terms of the Arrangement, out of money stock options were cancelled. F3 · derivative.exercise_date: 100% of the options vest fully on the date which is one year after the date of grant. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 21:11 UTC | RESPONSE BIOMEDICAL CORP RBM · Entity 180768 | Disposition to issuerCommon Stock | 73,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-16-042842 · rdgdoc.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the Agreement and Plan of Arrangement by and between the issuer and 1077801 B.C. Ltd., dated June 16, 2016 (the "Arrangement"), pursuant to which 1077801 B.C. Ltd. acquired all of the outstanding common shares of the issuer (other than those rolled over into the purchaser) in exchange for cash consideration of $1.12 CDN per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.